Originally posted in Drug Discovery News on January 26, 2026, by Marianne Baillargeon
Integrating patient-derived xenografts and organoids can help researchers identify responsive tumor subsets, anticipate resistance, and strengthen translational confidence before clinical testing.
Baillargeon, M., (2026) Reducing Uncertainty in Early Oncology with Patient-derived Systems - Crown Bioscience. https://blog.crownbio.com/reducing-uncertainty-in-early-oncology-with-patient-derived-systems
What if the next breakthrough in cancer treatment isn't a pill or infusion, but a precisely targeted radioactive payload that hunts down tumor cells l…
Read more
When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology…
Read more
Developing an oncology therapy requires a series of key decisions, each with the power to move a program forward or set it back. Pipelines are increas…
Read more
